PPARG and Hypoglycemia: Previously, it was reported that treatment with the PPARγ agonist pioglitazone augmented the incidence of hypoglycemia in diabetic women24 and that rosiglitazone showed a greater reduction of fasting plasma glucose (FPG) levels in women than in men25, suggesting that women have a greater sensitivity to treatment with PPARγ ligands.